Navigation Links
Sequenom Announces License And Marketing Agreements With Laboratoire Cerba In France
Date:5/30/2013

SAN DIEGO and ST OUEN L'AUMONE, France, May 30, 2013 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that it, along with its wholly owned subsidiary, Sequenom Center for Molecular Medicine (Sequenom CMM), has entered into technology licensing and marketing agreements with Laboratoire Cerba in France for noninvasive prenatal aneuploidy testing. These agreements will expand access to Sequenom CMM's MaterniT21™ PLUS laboratory-developed test and the technology used in the test to healthcare providers and their patients via Laboratoire Cerba's network in France, Belgium, Luxembourg and portions of the Middle East and Africa.

"This new relationship with Laboratoire Cerba, one of the leading diagnostics service providers in Europe, will enable us to leverage Laboratoire Cerba's strong network of facilities to provide healthcare providers and their patients with access to our innovative noninvasive prenatal testing (NIPT) technology," said William Welch , President and COO, Sequenom, Inc. "We look forward to collaborating with Cerba to continue to build upon the momentum we've seen with the adoption of our testing services worldwide."

Under the terms of the license agreement, Sequenom will license its cell-free fetal nucleic acid technology to Laboratoire Cerba to establish its noninvasive fetal aneuploidy testing service in France. Laboratoire Cerba will also have rights to market its noninvasive testing service in multiple countries, including France, Luxembo
'/>"/>

SOURCE Sequenom, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sequenom, Inc. Reports Financial Results For The First Quarter Of 2012
2. Sequenom Completes International Distribution Agreements To Expand Access To MaterniT21 PLUS Prenatal Testing Service
3. Sequenom Welcomes Myla Lai-Goldman, M.D., To Board Of Directors
4. Sequenom Announces Exercise In Full Of Over-Allotment Option And Completion Of Offering Of $130 Million Of 5.00% Convertible Senior Notes
5. Sequenom CMMs MaterniT21 PLUS LDT Now Reporting On Gender-Specific Chromosomal Abnormalities
6. Sequenom, Inc. Announces Date Of Fourth Quarter And Full Year 2012 Financial Results And Conference Call
7. Sequenom Announces Participation At The Barclays Global Healthcare Conference
8. Sequenom, Inc. Reports Financial Results For The Fourth Quarter And Full Year Of 2012
9. Morning Research on Sequenom, Peregrine Pharma, Onyx Pharma, and Inovio Pharma
10. Sequenom Announces Participation At The Bank Of America Merrill Lynch Health Care Conference
11. Sequenom, Inc. Reports Financial Results For The First Quarter Of 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... , April 21, 2015  Following is the daily ... LIFESAVING MEDICINE Profile ... important medicines — insulin —became available for general use ... of people suffering from diabetes. Insulin is a hormone ... processing of carbohydrates in the human body. It was ...
(Date:4/20/2015)... April 20, 2015 Research published today in ... Sciences (PNAS) demonstrates that technology invented by ... Casey Eye Institute can improve the clinical ... coherence tomography (OCT) angiography could largely replace current ... OHSU researchers found that OCT angiography ...
(Date:4/20/2015)... ALPHARETTA, Ga. , April 20, 2015  Halyard Health ... discussing financial results and business highlights for the first quarter ... company will issue a news release detailing first quarter results ... conference call will be hosted by Robert Abernathy , ... Chief Financial Officer. To join the live conference ...
Breaking Medicine Technology:U.S. Census Bureau Daily Feature for April 21 2Study shows new technology may improve management of leading causes of blindness 2Study shows new technology may improve management of leading causes of blindness 3Study shows new technology may improve management of leading causes of blindness 4Study shows new technology may improve management of leading causes of blindness 5Halyard Health Inc. To Webcast Conference Call Discussing First Quarter 2015 Financial Results 2
... Pompe Patients May Be Amenable to Chaperone ... ... Amicus Therapeutics, a,biopharmaceutical company developing small-molecule, orally administered,pharmacological chaperones for ... present positive results from an ex,vivo response study and three Phase ...
... Raven,biotechnologies, inc., a privately held company focused on ... for cancer,today announced that it has initiated a ... in combination with gemcitabine in the treatment of,patients ... Pancreatic Cancer Study will be conducted at approximately,20 ...
Cached Medicine Technology:Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220 2Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220 3Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220 4Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer 2Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer 3
(Date:4/21/2015)... 2015 With a growing number of ... Worldwide indicates that international political instability and terrorism top ... survey by Clements, a global insurance provider with 68 ... their country of citizenship, also found strong concern but ... health care insurance overseas . , Asked to choose ...
(Date:4/21/2015)... Pharmacy point of sale software provider ... Cooperative trade show, to be held April 30 through ... Management Solutions recently became an approved vendor with the ... of Sales and Marketing. Gross says that IPC hosts ... in the country -- and this new partnership will ...
(Date:4/21/2015)... Ramon, CA (PRWEB) April 21, 2015 ... announced Linda Burnes Bolton, DrPH, RN, FAAN, will keynote ... Transformation - in Long Beach, CA on October 26, ... President of the American Organization of Nurse Executives (AONE) ... As past president of the American Academy of Nursing ...
(Date:4/21/2015)... CA (PRWEB) April 21, 2015 ... solutions for biopharmaceutical development, today announced that the ... the University of Ottawa has acquired a Freeslate ... Screening Pressure Reactor (SPR) to accelerate current ... High-Throughput Experimentation Facility where they will be available to ...
(Date:4/21/2015)... April 21, 2015 “The warm summer season ... every mother want to look younger than her age? ... first line of defense. Signs of premature aging ... evidence of too much time spent in the sun without ... to cover up. The dangers of UV rays can ...
Breaking Medicine News(10 mins):Health News:Potential Expatriate Retirees Fear Political Violence, International Health Insurance Coverage 2Health News:Potential Expatriate Retirees Fear Political Violence, International Health Insurance Coverage 3Health News:Retail Management Solutions to Attend Upcoming Independent Pharmacy Cooperative Trade Show 2Health News:Retail Management Solutions to Attend Upcoming Independent Pharmacy Cooperative Trade Show 3Health News:Nationally Recognized Nurse Leader Linda Burnes Bolton to Present Keynote Address at CALNOC Conference 2Health News:University of Ottawa Selects Freeslate Reaction Screening System to Support High-Throughput Research at the Centre for Catalysis Research and Innovation 2Health News:University of Ottawa Selects Freeslate Reaction Screening System to Support High-Throughput Research at the Centre for Catalysis Research and Innovation 3Health News:Sun’s the Word this Mother’s Day Say’s SunGrubbies.com, a Leading Retailer of Sun Protection Products 2
... 18, 2007) New research published in the December ... Surgeons shows that outcomes of high-risk cancer operations in ... and published survival statistics, which may lead to unrealistic ... elderly. With this limited information, elderly patients and their ...
... Offer Relief from Menopausal Symptoms, ST. LOUIS, Dec. ... years, new research demonstrates that soy isoflavones may offer,them ... for,approximately 25 percent of the total female population in ... generation enter their early,forties, an unprecedented number of women ...
... Cyberonics, Inc. (Nasdaq:,CYBX) announced that effective December ... with Ethicon Endo-Surgery granting exclusive rights to,the company,s ... (VNS) for the treatment of obesity and two ... Ethicon Endo-Surgery has agreed to pay Cyberonics a ...
... CHAPEL HILL, N.C., Dec. 18 Many large ... to maintain ever-expanding,product portfolio. These alliances are developed ... pharmaceutical companies use,in-licensing deals to tap into expertise ... much needed, capital, development expertise, and market,insight to ...
... 18 Despite all the scientific,advancements in drug ... trip from the lab to the marketplace. To ... best-in-class pharmaceutical companies have learned,to inject commercial insights ... from Best Practices, LLC., "It,s clear early ...
... Mellor is one of,more than 400,000 people in the ... It,s, a debilitating disease that causes,paralysis, blindness, incontinence and ... Mellor, the founder of the Accelerated,Cure Project for Multiple ... raising the funds he needs to scratch "Develop a ...
Cached Medicine News:Health News:Study finds outcomes of high-risk cancer operations in 80-year-olds worse than reported 2Health News:News Flash on Hot Flashes: Soy Can Turn Down the Heat 2Health News:Cyberonics Licenses Obesity-Related Patents 2Health News:Cyberonics Licenses Obesity-Related Patents 3Health News:Developing Excellence in Alliance 2Health News:Using Early Stage Commercialization Activities to Build Long-Term Success for the Bottom Line 2Health News:This Holiday Season Some Dream of a White Christmas - The Accelerated Cure Project Dreams of Developing a Cure for Multiple Sclerosis 2Health News:This Holiday Season Some Dream of a White Christmas - The Accelerated Cure Project Dreams of Developing a Cure for Multiple Sclerosis 3
... The SG210D combines a slab gel dryer ... convenient gel drying without any hardware setup. The ... fixed in acetic acid, protein/agarose gels, and multiple ... in 60 minutes or less. , Completely ...
Inquire...
... system, Hoefers Easy Breeze can dry as many as ... Mini-Gels (8 x 10 cm) at a time. , ... drying oven, a specially designed loading platform, and two ... no awkward connections., The Gel Frame is largely responsible ...
... HydroTech™ gel drying system, 220-240 V, includes Model ... The Model 583 gel dryer is a vacuum-based ... x 45 cm with variable temperature control and ... a water-based vacuum pump used for pulling vacuum ...
Medicine Products: